Key upcoming readouts to shape outlook

SynAct Pharma delivered a milestone-rich Q126, advancing resomelagon across multiple clinical programmes while moving closer to several potential re-rating catalysts. Key highlights included the initiation of the RESPIRE study in hospitalised patients with viral respiratory insufficiency and RESOVIR-2 in dengue fever, alongside completion of enrolment in the Phase IIb ADVANCE trial in newly diagnosed RA. Investor attention now turns to the ADVANCE top-line readout in June, which we view as the company’s most important near-term catalyst. Positive data could validate SynAct’s inflammation-resolution approach, while subsequent top-line data from the RESPIRE trial in Q3 will be key to establishing the asset’s platform applicability across b...